Back to mobile site

BMO Capital Starts Ionis Pharmaceuticals (IONS) at Outperform

April 6, 2016 4:24 PM EDT Send to a Friend
BMO Capital initiates coverage on Ionis Pharmaceuticals (NASDAQ: IONS) with a Outperform rating and a price target of $55.00.Analyst Do ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE

Member Login